Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.58 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17659980 | 0.87 | MAPT (0.48) | LOXL2CYP3A4HIF1AKDM4EALDH1A1 | |
| SCHEMBL23496972 | 0.85 | LOXL2 (0.55) | LOXL2NCF1HTR1AADRA1DADRA1A | |
| SCHEMBL6703259 | 0.81 | LOXL2 (0.59) | LOXL2NCF1HTR1AADRA1DADRA1A | |
| SCHEMBL22955389 | 0.81 | LOXL2 (0.40) | LOXL2NCF1HTR1AADRA1DADRA1A | |
| SCHEMBL28157122 | 0.81 | LOXL2 (0.58) | LOXL2NCF1HTR1AADRA1DADRA1A | |
| SCHEMBL21849303 | 0.80 | LOXL2 (0.37) | LOXL2AAK1 | |
| SCHEMBL6017487 | 0.80 | NR3C1 (0.49) | LOXL2NCF1HTR1AADRA1DADRA1A | |
| SCHEMBL12776083 | 0.79 | NPC1 (0.36) | LOXL2KDM4ELMNASMN1; SMN2NPSR1 | |
| SCHEMBL12251101 | 0.79 | LOXL2 (0.51) | LOXL2NCF1HTR1AADRA1DADRA1A | |
| SCHEMBL28292734 | 0.79 | LOXL2 (0.47) | LOXL2NCF1HTR1AADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067656-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-02-29 | — | — | US | disclosed |
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20210230183-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-07-29 | — | — | US | disclosed |
| US-10828288-B2 | Hydrazone derivatives for the treatment of cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-11-05 | — | — | US | disclosed |
| US-10729671-B2 | Zinc complexes of hydrazones and (thio)semicarbazones and their use for the treatment of cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-08-04 | — | — | US | disclosed |
| US-10450293-B2 | Chemokine CXCR4 and CCR5 receptor modulators and uses related thereto | EMORY UNIVERSITY (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180171190-A1 | FORMULATIONS AND APPLICATIONS OF WET-ADHESIVES | ACatechol, Inc. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20170137401-A1 | Chemokine CXCR4 and CCR5 Receptor Modulators and Uses Related Thereto | EMORY UNIVERSITY (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170137401-A1 | Chemokine CXCR4 and CCR5 Receptor Modulators and Uses Related Thereto | EMORY UNIVERSITY (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170096415-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | UNIV YALE (US) | 2017-04-06 | — | — | US | disclosed |
| US-9562038-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus | YALE UNIVERSITY (US) | 2017-02-07 | — | — | US | disclosed |
| US-8980848-B2 | Flavonoid dimers and their use | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2015-03-17 | — | — | US | disclosed |
| US-8895580-B2 | Quinolinone-pyrazolone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20130045935-A1 | FLAVONOID DIMERS AND THEIR USE | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2013-02-21 | — | — | US | disclosed |
| US-20130045935-A1 | FLAVONOID DIMERS AND THEIR USE | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2013-02-21 | — | — | US | disclosed |
| US-20120196845-A1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-08-02 | — | — | US | disclosed |
| US-7408025-B2 | Lipopeptides as antibacterial agents | CUBIST PHARMACEUTICALS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10729671-B2 | Zinc complexes of hydrazones and (thio)semicarbazones and their use for the treatment of cancer | SLC39A3, SLC39A7, SLC30A7 | LOXL2 2587/4885NCF1 791/4885HTR1A 4726/4885 |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | LOXL2 1686/4885NCF1 441/4885HTR1A 2852/4885 |
| US-20210230183-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | LOXL2 2593/4885NCF1 1273/4885HTR1A 4839/4885 |
| US-20130045935-A1 | FLAVONOID DIMERS AND THEIR USE | DHFR, CCNY, ETFB | LOXL2 2536/4885NCF1 707/4885HTR1A 4287/4885 |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, ALKBH1 | LOXL2 3550/4885NCF1 2986/4885HTR1A 2622/4885 |
| US-10450293-B2 | Chemokine CXCR4 and CCR5 receptor modulators and uses related thereto | CXCR4, CCR5, CXCR3 | LOXL2 1843/4885NCF1 1667/4885HTR1A 1327/4885 |
| US-20120196845-A1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, CHRNA5 | LOXL2 4821/4885NCF1 1949/4885HTR1A 27/4885 |
| US-20240067656-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | LOXL2 2593/4885NCF1 1273/4885HTR1A 4839/4885 |
| US-20170096415-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | CD4, HAVCR2, CD2 | LOXL2 3329/4885NCF1 440/4885HTR1A 3842/4885 |
| US-20170137401-A1 | Chemokine CXCR4 and CCR5 Receptor Modulators and Uses Related Thereto | CXCR4, CCR5, CXCR3 | LOXL2 1843/4885NCF1 1667/4885HTR1A 1327/4885 |
| US-10828288-B2 | Hydrazone derivatives for the treatment of cancer | H1-3, H1-5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | LOXL2 2269/4885NCF1 919/4885HTR1A 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.